Home >> News >> Business >> Glioblastoma Multiforme Market is Expected to Reach USD 898.9 Mn by 2022 – Credence Research

Glioblastoma Multiforme Market is Expected to Reach USD 898.9 Mn by 2022 – Credence Research

The latest market report published by Credence Research, Inc. “Global Glioblastoma Multiforme Market – Growth, Share, Opportunities, Pipeline Analysis, Competitive Analysis, and Forecast, 2016 – 2022,” the glioblastoma multiforme market was valued at USD 352.2 Mn in 2015, and is expected to reach USD 898.9 Mn by 2022, expanding at a CAGR of 10.95% from 2016 to 2022.

Browse the full report Glioblastoma Multiforme Market – Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016 – 2022 at http://www.credenceresearch.com/report/glioblastoma-multiforme-market

Market Insights

Glioblastoma multiforme (GBM) belongs to a group of brain tumors known as gliomas that grows from a type of brain cell called a glial cell. It is the most common primary brain tumor in adults and also the most aggressive form of brain tumor. According to U.S. National Cancer Institute, GBM is considered as the most aggressive form of brain cancer which represents 15.4% of all primary brain tumors and about 60% – 75% of all astrocytoma and shows rapid growth rate of benign cells in the organ. According to World Health Organization (WHO), the incidence of glioblastoma multiforme (GBM) is 2 to 3 per 100,000 people in the United States and Europe. Overall GBM accounts for 12 to 15% of all intracranial tumors and 50 to 60% of astrocytic tumors. In year 2015, temozolomide accounted for the largest market share of the global glioblastoma multiforme market. The key advantages possessed by temozolomide are delayed progression without impacting the quality of life and less adverse effects compared to other molecules. Medical practitioners suggest that, combination radiotherapy and temozolomide chemotherapy is currently the standard of care for most patients suffering from GBM. On the other hand, the geographical analysis of glioblastoma multiforme market projected North America and Europe as the dominant regions followed by Asia-Pacific.  The key factors driving the glioblastoma multiforme market include developed research and development facilities, upcoming drug launches, rising incidences of the central nervous system cancers in the geriatric population. Thus, upcoming drugs and ongoing research developments are expected to drive the overall market og glioblastoma multiforme market across the globe.

Related Reports:

Precision Medicine Market

Clinical Laboratory Services Market

Bioinformatics Market

Leave a Reply

Your email address will not be published. Required fields are marked *